With the advances of tumor DNA sequencing, there is a growing interest in personalized cancer therapy with genomically matched treatments and it would be suitable to explore the combination of a third-generation tyrosine kinase inhibitor targeting EGFR with cetuximab and bevacizumab in preselected patients with EGFR activating mutations and excluding patients with concomitant alterations that might confer resistance to the combination, such as KRAS mutations. This evidence concerns the gene KRAS and neoplasm.